Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of Complications in Patients Undergoing Surgical Treatment of Hepatic Tumors
2025-524477-17-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of technetium-99m diethylenetriaminepentaacetic acid galactosyl human serum albumin in hepatic neoplasm, sponsored by Rigshospitalet. Planned start Aug 2026; status: authorised.
02
Drugs
technetium-99m diethylenetriaminepentaacetic acid galactosyl human serum albumin
03
Conditions
hepatic neoplasm
Beyond the preview
Go deeper on 2025-524477-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524477-17-00.